Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 144.29M | 137.74M | 136.36M | 132.10M | 127.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 144.29M | 137.74M | 136.36M | 132.10M | 127.04M |
| Cost of Revenue | 55.33M | 55.61M | 69.18M | 87.60M | 100.24M |
| Gross Profit | 88.95M | 82.13M | 67.18M | 44.50M | 26.81M |
| SG&A Expenses | 100.48M | 90.45M | 95.97M | 109.25M | 119.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.81M | 146.06M | 165.15M | 196.85M | 220.06M |
| Operating Income | -11.53M | -8.32M | -28.79M | -64.75M | -93.02M |
| Income Before Tax | -13.58M | -27.97M | -48.13M | -80.95M | -110.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.58 | -27.97 | -48.13 | -80.95 | -110.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.58M | -27.97M | -48.13M | -80.95M | -110.56M |
| EBIT | -11.53M | -8.32M | -28.79M | -64.75M | -93.02M |
| EBITDA | -9.04M | -5.70M | -26.02M | -61.88M | -90.12M |
| EPS Basic | -0.09 | -0.18 | -0.32 | -0.61 | -0.87 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.13 | -0.31 | -0.47 |
| EPS Diluted | -0.09 | -0.18 | -0.32 | -0.61 | -0.87 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.13 | -0.31 | -0.47 |
| Average Basic Shares Outstanding | 609.49M | 609.53M | 601.69M | 569.11M | 537.16M |
| Average Diluted Shares Outstanding | 609.49M | 609.53M | 601.69M | 569.11M | 537.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
